SCHEMBL24309603

SCHEMBL24309603

Cc1ccccc1-c1cc(Oc2ccccc2)nc(NS(=O)(=O)c2cccc(N)c2)n1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.45
▸ TSHR P16473 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ MAPT P10636 2/20 0.43
▸ PGR P06401 2/20 0.42
▸ PKM P14618 2/20 0.40
▸ HTR6 P50406 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ PIK3C2B O00750 1/20 0.40
▸ PIK3C2G O75747 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ GPR39 O43194 1/20 0.39
▸ PRMT1 Q99873 1/20 0.39
▸ FFAR4 Q5NUL3 1/20 0.39
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26807167 0.95 MAPT (0.45) POLBTSHRSMN1; SMN2MAPTPGR
SCHEMBL26807086 0.92 TSHR (0.49) POLBTSHRSMN1; SMN2MAPTPGR
SCHEMBL26807160 0.92 CA12 (0.41) POLBTSHRSMN1; SMN2MAPTPGR
SCHEMBL29567277 0.91 PGR (0.42) POLBTSHRSMN1; SMN2MAPTPGR
SCHEMBL26807133 0.91 PGR (0.42) POLBTSHRSMN1; SMN2MAPTPGR
SCHEMBL29702903 0.91 ALDH1A1 (0.43) POLBTSHRSMN1; SMN2ALDH1A1
SCHEMBL24330515 0.91 ALDH1A1 (0.43) POLBTSHRSMN1; SMN2ALDH1A1
SCHEMBL29567014 0.91 TSHR (0.39) POLBTSHRSMN1; SMN2MAPTPGR
SCHEMBL24309292 0.91 TSHR (0.39) POLBTSHRSMN1; SMN2MAPTPGR
SCHEMBL26810957 0.90 TSHR (0.54) TSHRSMN1; SMN2MAPTPGRPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B POLB 3593/4885TSHR 1755/4885SMN1; SMN2 4847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback